New Drugs Against COVID-19 on Clinical Trial

HT

Mini desc

Want to know more?

Interactive content on WeChat


New Drugs Against COVID-19 

on Clinical Trial

Zhang Xin Min

Director of China National Center for Biotechnology Development under the Ministry of Science and Technology

Several antiviral drugs have been applied in clinical trials against the novel coronavirus disease (COVID-19), and some have shown fairly good results.


Chinese researchers have narrowed down their focus to a few existing drugs, including Chloroquine Phosphate, Favipiravir and Remdesivir, after multiple rounds of screening, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference on the new virus.


The preliminary clinical results show that Chloroquine Phosphate is quite effective in treating novel coronavirus pneumonia.

It is now under clinical trials in more than 10 hospitals in Beijing and Guangdong, which will start to enroll a total of 100 patients. 

Clinical trials on the drug will also be launched in central China's Hunan Province soon, said Zhang during the press conference.


Favipiravir, an influenza drug available on overseas markets, has been put in a clinical trial in Shenzhen, south China's Guangdong Province, with 70 patients enlisted, he said.


The initial outcome of the trial shows the drug has relatively effective and with low adverse reactions.


Remdesivir is developed against Ebola infections by Gilead Sciences, an American pharmaceutical company. It has shown fairly good antiviral activity against the novel coronavirus at the cellular level.


The China-Japan Friendship Hospital have been authorized to conduct a clinical trial on the drug in over 10 hospitals in Wuhan, the center of the epidemic in central China's Hubei Province.


"Next, we will make timely recommendations on the COVID-19 treatment according to the results of these clinical trials," Zhang said.


According to Zhang, the researchers scanned more than 70,000 drugs or compounds through computer simulations and in vitro enzyme activity tests, and selected 5,000 potentially effective drug candidates.


Then they were tested at the cellular level against the common coronavirus infection, and about 100 drugs were chosen for further experiments, which helped to select the final drugs for clinical trials, Zhang said.


The most urgent scientific research task is to improve the cure rate and reduce the mortality, which rely on effective clinical treatments.

New products and technologies have been adopted to treat severe and critically ill patients, a key approach to reduce mortality, and some have achieved good clinical results, he said.


A cause of death for severe and critically ill patients infected with the COVID-19 is "cytokine storm", which is an overreaction of the immune system, according to Zhou Qi, an academician with the Chinese Academy of Sciences (CAS).


We are also searching for existing drugs that can curb the appearance of cytokine storm, including drugs against rheumatism. Some of the drugs that are proven effective at the cellular level have been applied in clinical trials," Zhou said at the press conference.

A trial has been conducted on 14 severe or critically ill patients aged up to 82 in an affiliated hospital of the University of the CAS, and the results appeared encouraging, Zhou said.


Now, a multicenter, randomized, parallel-group clinical trial is underway. If these initial results show a drug is effective, the process may be speed up and provide severe patients with effective treatments as soon as possible.


Dont forget to share your comments with us!

> Was this article any help to you?

> Is there any corrections to this article?

Photos

5e4a9e62a5dd4

User comments

There are no user comments for this listing.
Already have an account?
Anti Spam Check
Don't want to answer that question every time?
Register an account
It's FREE and give you access to advanced features
Comments
You will be able to upload media right after you submit your comment.